[Recent advance in peripheral T-cell lymphoma, not otherwise specified].
Zhan
He-qin
HQ
Li
Xiao-qiu
XQ
Zhu
Xiong-zeng
XZ
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D015703:Antigens, CD / Q000378:metabolism*; D019011:Antigens, CD7 / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017252:CD3 Complex / Q000378:metabolism; D018956:CD5 Antigens / Q000378:metabolism; D000074301:CD52 Antigen; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D006023:Glycoproteins / Q000378:metabolism; D006689:Hodgkin Disease / Q000378:metabolism / Q000473:pathology; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000378:metabolism / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D011241:Prednisone / Q000627:therapeutic use; D054367:Receptors, CXCR3 / Q000378:metabolism; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D019011:Antigens, CD7; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D017252:CD3 Complex; D018956:CD5 Antigens; D000074301:CD52 Antigen; C000613862:CD52 protein, human; C515187:CXCR3 protein, human; D006023:Glycoproteins; D054367:Receptors, CXCR3; D000074323:Alemtuzumab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone